3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Lymphoid
2
Dermatologic
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Endocrine
1
CNS
1
Conditions
Differentiated Thyroid Cancer
1
Interventions
Cisplatin
57
pembrolizumab
54
Cetuximab
43
Radiotherapy
35
Docetaxel
21
Radiotherapy, Intensity-Modulated
20
Paclitaxel
19
Nivolumab
18
Fluorouracil
18
Carboplatin
17
Radiation
14
Radiosurgery
9
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Everolimus
8
Biopsy
8
Surgical Procedures, Operative
7
Oxaliplatin
7
Cyclophosphamide
7
durvalumab
6
avelumab
6
Erlotinib Hydrochloride
6
Capecitabine
6
spartalizumab
5
epacadostat
5
Surveys and Questionnaires
5
Platinum
5
Immunoglobulin G
5
Gefitinib
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
AZD 6244
×
Head & Neck
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts